Fariborz Kamal
Chief Technical AdvisorDr. Fariborz Kamal, also known as Fred, Ph.D., had been its Chief Operating Officer at 4D Molecular Therapeutics, Inc. since February 2020 until December 31, 2025 and served as its President since September 2022 until December 31, 2025 and serves as its Chief Technical Advisor since January 01, 2026. He had been Chief Technical Officer at 4D Molecular Therapeutics, Inc. since October 2018 until February 2020 and served as its Head of Regulatory and Quality until 2020 Dr. Kamal previously served as Senior Vice President of Quality and Regulatory CMC for AveXis Inc., a gene therapy company, from May 2017 to August 2018. Prior to AveXis, Dr. Kamal served as the Vice President of Quality for Juno Therapeutics from May 2015 to April 2017 and prior to that Dr. Kamal served as the Vice President of Quality and Regulatory CMC for Intermune Inc. from January 2013 through March 2015. Dr. Kamal received his B.S. in Chemistry from San Jose State University in 1986. Dr. Kamal received his M.Sc. in Chemistry from The American University in 2000. He received his Ph.D. in Chemistry from The American University in 2003.
Positions
- Company Name4D Molecular Therapeutics, Inc.Stock CodeFDMTPositionChief Technical Advisor
